Navigation Links
Cardium Completes Preferred Stock Financing
Date:7/19/2013

SAN DIEGO, July 19, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced the completion of the second tranche of its previously described registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the offering to approximately $4.0 million.  The shares were offered and sold pursuant to a prospectus supplement dated April 5, 2013 of a prospectus dated August 27, 2010, which is part of a registration statement on Form S-3 (Registration No. 333-168693) that was declared effective by the SEC on August 27, 2010.  A detailed description of the terms of the securities purchase agreement as well as the rights, privileges and preferences of the Series A Convertible Preferred Stock is contained in the Company's Current Report on Form 8-K which was filed with the SEC on April 5, 2013. 

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

About Cardium         

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes LifeAgain medical data analytics, Tissue Repair Company, Cardium Biologics, and the Company's To Go Brands® nutraceutical business. The Company's lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
3. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
4. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
5. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
6. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
7. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
8. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
9. Cardium Receives ISO Certification for Excellagen
10. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
11. Cardium Presents Year-End 2012 Financial Results And Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
(Date:7/22/2014)... ,  July 22, 2014 The ... Thomson Reuters , the world,s leading provider ... today announced Cortellis Clinical Trials Intelligence ... an industry-first milestone with the documentation of ... pharmaceutical professionals with greater and quicker access ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
(Date:7/22/2014)... of research at the University of Utah,s John A. ... Society of Eye Research (ISER) as the recipient of ... International Award in Retina Research., The award recognizes lifetime ... significant contribution to the understanding of vitreoretinal diseases or ... the ISER Biennial Meeting in San Francisco, where Marc ...
(Date:7/22/2014)... comes to heart disease, Dr. Ross Feldman says women are ... disease was a men,s-only disease, however, data has shown that ... heart disease and are less likely to be adequately diagnosed ... week in the British Journal of Clinical Pharmacology ... women and helps to identify which women are more prone ...
(Date:7/22/2014)... 22, 2014) -- The American Society of Hematology (ASH) ... H. Coulter Award for Lifetime Achievement in Hematology, to ... Island Jewish (LIJ) School of Medicine for his 50-year ... education and mentoring, and exceptional patient care. , ... Hematology is bestowed on an individual who has been ...
(Date:7/22/2014)... 2014 Legislation backed by the ... Local Pharmacies Act of 2014”) championing so-called “any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). , The drugstore ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Gene variant identified as a heart disease risk factor for women 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... multispecialty medical group in Southern California, announced the opening of its ... Monrovia. , ... Torrance, CA (PRWEB) December 16, 2008 ... Southern California, announced the opening of its newest medical office ...
... portal that features the latest news, facts and nutritional updates about ... acai plant and the acai berry fruit to help the general ... ... Dallas, TX (PRWEB) December 16, 2008 -- The announcement ...
... Inc.(CTI),(Nasdaq and MTA: CTIC) announced today they have ... a 50/50 owned joint venture, RIT,Oncology LLC (LLC), ... United States. In connection with the closing, ... and will receive an,additional $7.5 million in early ...
... Dec. 15 Today, the U.S. Food,and Drug Administration ... along with diet to help lower triglycerides,and LDL cholesterol, ... TRILIPIX is the first and only fibrate to ... In certain patients, treatment guidelines,recommend the combination of a ...
... Calif.) -- A secondary analysis of a large, multicenter ... fruits, vegetables and fiber and somewhat lower in fat ... of recurrence in a subgroup of early-stage breast cancer ... by approximately 31 percent. These patients typically have higher ...
... say , , MONDAY, Dec. 15 (HealthDay News) -- Men ... spread beyond the wall of the prostate gland -- ... risk of dying in half, a new study has ... much longer, the Swedish research team concluded. In fact, ...
Cached Medicine News:Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 4Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 5Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 2Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 3Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 2Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 3
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design ... Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... (ul) ...
Medicine Products: